Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06242834
Status:
RECRUITING
Last Update Posted:
2024-02-05
First Post:
2024-01-29
Brief Title:
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkins Lymphoma
Sponsor:
Northwestern University
Organization:
Northwestern University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-24
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-04-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-04-24
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-29
First Submit QC Date:
January 29 2024
Study First Post Date:
2024-02-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-04
Last Update Post Date:
2024-02-05
Last Update Post Date Type:
ACTUAL